|
|
Volumn 10, Issue 2, 2006, Pages 116-118
|
|
Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CLOPIDOGREL;
ACUTE CORONARY SYNDROME;
ARTICLE;
BLEEDING;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG POTENTIATION;
ECONOMIC ASPECT;
EVIDENCE BASED MEDICINE;
FOLLOW UP;
HEALTH CARE COST;
HUMAN;
LIFE EXPECTANCY;
LONG TERM CARE;
MEDICAL DECISION MAKING;
OUTCOMES RESEARCH;
PERCUTANEOUS CORONARY INTERVENTION;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
ST SEGMENT;
THROMBOCYTE ACTIVATION;
|
|
EID: 33744528328
PISSN: 13612611
EISSN: 15322173
Source Type: Journal
DOI: 10.1016/j.ebcm.2006.04.033 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|